Profil
Reinier Beeuwkes is the founder of Braintree Laboratories, Inc., which was founded in 1982.
He holds the title of Director at Braintree Laboratories, Inc. Dr. Beeuwkes's current job is Director at Ischemix, Inc., where he started in 2002.
Dr. Beeuwkes's former job was Chairman & Chief Executive Officer at Citius Pharmaceuticals, Inc.
Postes actifs de Reinier Beeuwkes
| Sociétés | Poste | Début |
|---|---|---|
Braintree Laboratories, Inc.
 Braintree Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Braintree Laboratories, Inc. manufactures pharmaceutical products and drugs. Its products include SUPREP, NuLYTELY and GoLYTELY. The company was founded by Harry Keegan III and Reinier Beeuwkes in 1982 and is headquartered in Braintree, MA. | Fondateur | 01/01/1982 |
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Directeur/Membre du Conseil | 01/01/2002 |
Anciens postes connus de Reinier Beeuwkes
| Sociétés | Poste | Fin |
|---|---|---|
| CITIUS PHARMACEUTICALS, INC. | Directeur Général | 12/09/2014 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CITIUS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Braintree Laboratories, Inc.
Braintree Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Braintree Laboratories, Inc. manufactures pharmaceutical products and drugs. Its products include SUPREP, NuLYTELY and GoLYTELY. The company was founded by Harry Keegan III and Reinier Beeuwkes in 1982 and is headquartered in Braintree, MA. | Health Technology |
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
